Aclaris Therapeutics, Inc. (ACRS) vs ArriVent BioPharma, Inc. (AVBP)
A side-by-side comparison of Aclaris Therapeutics, Inc. and ArriVent BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$3.78HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
AVBP
ArriVent BioPharma, Inc.
$14.42HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — ACRS vs AVBP
growth of $100 · dividends reinvested · last 3yACRS +238.9% (+50.2%/yr)AVBP +42.3% (+12.5%/yr)ACRS compounded faster over this window
ACRS AVBP
ACRS vs AVBP: by the numbers
- •AVBP is the larger company ($672M vs $527M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -921.50% net margin).
Metrics side by side
Valuation
| Metric | ACRS | AVBP |
|---|---|---|
| P/S ratio | 64.17 | N/A |
| P/B ratio | 4.23 | 1.83 |
Profitability
| Metric | ACRS | AVBP |
|---|---|---|
| Gross margin | 73.28% | 0.00% |
| Operating margin | -975.91% | 0.00% |
| Net margin | -921.50% | 0.00% |
| ROE | -60.79% | -44.63% |
| ROIC | -56.99% | -47.96% |
Growth (annualized)
| Metric | ACRS | AVBP |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | N/A |
| Total return CAGR (5Y) | -24.23% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.